CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Gelesis Holdings Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Gelesis Holdings Inc
501 Boylston Street, Suite 6102
Phone: (857) 327-7737p:857 327-7737 BOSTON, MA  02116  United States Ticker: GLSHQGLSHQ
Filed for Bankruptcy on 10/30/2023
This company was Merged or Acquired on 1/14/2022.
Case #23-11787, filed in the U.S. Bankruptcy Court for the District of Delaware (Chapter 7)
This is a Subsidiary, click here for the Parent Company
Business Summary
Gelesis Holdings, Inc. is a commercial stage biotherapeutics company built for consumer engagement. The Company focuses on advancing superabsorbent hydrogel therapeutics for chronic gastrointestinal (GI) diseases including excess weight, type two diabetes, Nonalcoholic Fatty Liver Disease (NAFLD)/ Nonalcoholic Steatohepatitis (NASH), functional constipation (FC), and inflammatory bowel disease. Its product, Plenity, is an orally administered capsule. Plenity is available by prescription via a telehealth consultation with a physician trained in weight management support, with free, unlimited follow-up visits as needed. Consumers can visit myplenity.com for online consultations. Its other pipeline candidate includes GS200 for weight loss in prediabetes and type two diabetes. It is also developing GS300 for the treatment of NAFLD and NASH, and GS500 for the treatment of Functional Constipation (FC).

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202312/31/2022YesYesYes--

Industries
SIC Code Description
2834 Pharmaceutical preparations
6770 Blank checks
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Chief Executive Officer, Interim Principal Financial Officer, Interim Principal Accounti YishaiZohar 60 8/15/2023 1/1/2022
Chief Operating Officer, Chief Commercial Officer DavidPass 1/1/2022 1/1/2022
Co-Inventor, Lead Project Scientist AlessandroSannino 51 1/1/2022 1/1/2022
5 additional Officers and Directors records available in full report.

Business Names
Business Name
CPSR
CPSR U
Gelesis S.r.l.
4 additional Business Names available in full report.

General Information
Number of Employees: 93 (As of 12/31/2022)
Outstanding Shares: 73,335,110 (As of 8/11/2023)
Shareholders: 35
Stock Exchange: OTC
Federal Tax Id: 844730610
Fax Number: (302) 636-5454


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, April 23, 2024